Results 271 to 280 of about 29,210 (297)
Ibrutinib promising in subtype of DLBCL [PDF]
The Lancet Oncology, 2015 Patients with the activated B-celllike (ABC) subtype of diff use large B-cell lymphoma were more likely to respond to ibrutinib than were those with the germinal centre B-celllike (GCB) subtype of the disease, according to results of a phase 2 study.
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Ibrutinib: targeting the hidden CLL
Blood, 2014In this issue of Blood , Herman et al elucidate the in vivo effects of ibrutinib (a BTK inhibitor) in various disease compartments of patients with chronic lymphocytic leukemia (CLL).[1][1] The study validates the differential impact of ibrutinib in various tumor compartments of patients treated ...
openaire +3 more sources
Current Treatment Options in Oncology, 2014
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or ...
Kristie A. Blum, Kami J. Maddocks
openaire +2 more sources
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or ...
Kristie A. Blum, Kami J. Maddocks
openaire +2 more sources
Risk of Major Bleeding with Ibrutinib
Clinical Lymphoma Myeloma and Leukemia, 2018The Bruton tyrosine kinase inhibitor, ibrutinib, is an effective therapy against mature B-cell malignancies. Although generally well tolerated, serious bleeding emerged during developmental clinical trials as an unexpected, although uncommon, adverse event.
Jeremy M Sen +8 more
openaire +3 more sources
Ibrutinib: First Global Approval
Drugs, 2014Ibrutinib (Imbruvica™) is a small molecule, first-in-class, once-daily, orally available, Bruton's tyrosine kinase inhibitor that is under development for the treatment of B cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL), as well as multiple myeloma (MM), follicular
Mark Sanford, Fiona Cameron
openaire +2 more sources
New Approved Indication for Ibrutinib
AJN, American Journal of Nursing, 2014* Ibrutinib (Imbruvica) has been approved to treat chronic lymphocytic leukemia in patients who've received treatment at least once with other drug therapy. * Common adverse effects are numerous and include thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory tract infection, fatigue, musculoskeletal pain, rash, fever ...
openaire +3 more sources
Ibrutinib in B lymphoid malignancies
Expert Opinion on Pharmacotherapy, 2015Most lymphomas and lymphoid leukemias are of B cell origin. Indolent B cell lymphomas, most commonly follicular lymphoma but including Waldenstrom's macroglobulinemia and mantle cell lymphoma, as well as chronic lymphocytic leukemia, are incurable with standard therapy. New treatments are needed.
openaire +3 more sources
Overcoming ibrutinib resistance
Science-Business eXchange, 2014The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.
openaire +2 more sources
Ibrutinib for Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2016Antonio Cuneo +2 more
openaire +6 more sources